Assessment of Cancer Screening : : A Primer.
Saved in:
: | |
---|---|
Place / Publishing House: | Cham : : Springer International Publishing AG,, 2022. ©2022. |
Year of Publication: | 2022 |
Edition: | 1st ed. |
Language: | English |
Online Access: | |
Physical Description: | 1 online resource (138 pages) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
LEADER | 07025nam a22003973i 4500 | ||
---|---|---|---|
001 | 5006947060 | ||
003 | MiAaPQ | ||
005 | 20240229073845.0 | ||
006 | m o d | | ||
007 | cr cnu|||||||| | ||
008 | 240229s2022 xx o ||||0 eng d | ||
020 | |a 9783030945770 |q (electronic bk.) | ||
020 | |z 9783030945763 | ||
035 | |a (MiAaPQ)5006947060 | ||
035 | |a (Au-PeEL)EBL6947060 | ||
035 | |a (OCoLC)1310845707 | ||
040 | |a MiAaPQ |b eng |e rda |e pn |c MiAaPQ |d MiAaPQ | ||
050 | 4 | |a RC254-282 | |
100 | 1 | |a Marcus, Pamela M. | |
245 | 1 | 0 | |a Assessment of Cancer Screening : |b A Primer. |
250 | |a 1st ed. | ||
264 | 1 | |a Cham : |b Springer International Publishing AG, |c 2022. | |
264 | 4 | |c ©2022. | |
300 | |a 1 online resource (138 pages) | ||
336 | |a text |b txt |2 rdacontent | ||
337 | |a computer |b c |2 rdamedia | ||
338 | |a online resource |b cr |2 rdacarrier | ||
505 | 0 | |a Intro -- Foreword -- Preface -- Acknowledgments -- Contents -- Contents -- Contents -- 1: Foundations -- 1.1 Cancer -- 1.2 Cancer Statistics -- 1.3 Cancer Screening -- 1.4 Population-Based Cancer Screening -- 1.5 Choosing the Cancers for Which We Screen -- 1.6 Choosing Who to Screen -- 1.7 The Cancer Screening Process -- 1.8 Cancer Screening Tests -- 1.9 Organized Screening Programs Versus Opportunistic Screening -- 1.10 Benefit Versus Harm -- 1.11 Efficacy and Effectiveness of Cancer Screening -- 1.12 Cancer Screening: Turning Healthy People Into Cancer Patients -- References -- 2: Behind the Scenes -- 2.1 A Simple Model of the Natural History of Cancer -- 2.2 Three Important Phenomena in Screen Detection of Cancer -- 2.2.1 Lead Time -- 2.2.2 Length-Weighted Sampling -- 2.2.3 Overdiagnosis -- 3: Performance Measures -- 3.1 The Building Blocks of Performance Measures -- 3.1.1 Cancer Screening Test Result -- 3.1.2 Cancer: Present or Not? -- 3.2 Calculating Cancer Screening Performance Measures -- 3.2.1 The Formulas -- 3.2.2 The Relationship Between PPV, NPV, and Prevalence -- 3.2.3 The Implications of Low PPV -- 3.2.4 Can PPV Be Improved? -- 3.3 ROC Curves and AUC -- 3.3.1 ROC Curves -- 3.3.2 Calculating AUC -- 3.4 Performance Measures: Evidence or Not? -- References -- 4: Population Measures: Definitions -- 4.1 Intermediate Outcomes -- 4.1.1 Cancer Incidence -- 4.1.2 Calculating a Cancer Incidence Rate: A Fictional Example -- 4.1.3 Stage Distribution -- 4.1.4 Case Survival -- 4.2 Definitive Outcomes -- 4.2.1 Cause-Specific and all-Cause Mortality -- 4.2.2 Calculating Mortality Rates: A Fictional Example -- References -- 5: Population Measures: Cancer Screening's Impact -- 5.1 Cancer Screening's Impact on Intermediate Outcomes -- 5.1.1 Cancer Incidence -- 5.1.2 Cancer Incidence Example. | |
505 | 8 | |a 5.1.3 Stage at Diagnosis -- 5.1.4 Stage at Diagnosis Example -- 5.1.5 Case Survival -- 5.1.6 Case Survival Example -- 5.2 Cancer Screening's Impact on Definitive Outcomes -- 5.2.1 Mortality Rates and the Three Screening Phenomena -- 5.2.2 Cause-Specific Mortality Rates -- 5.2.3 Sticking Diagnosis, Slippery Linkage, and Assessment of Cancer Screening -- 5.2.4 Cause of Death Review -- 5.2.5 Cause-Specific Mortality Rates: Definitive Enough? -- 5.2.6 All-Cause Mortality -- References -- 6: Experimental Research Designs -- 6.1 An Overview of Experimental Study Designs -- 6.2 Individual-Level Randomized Controlled Trials of Screening -- 6.2.1 Design Features -- 6.2.2 Analysis Features -- 6.2.3 Strengths and Weaknesses -- 6.2.4 Example of an Individual-Level Cancer Screening RCT -- 6.3 Cluster-Level Randomized Controlled Trials of Cancer Screening -- 6.3.1 Design Features -- 6.3.2 Analysis Features -- 6.3.3 Strengths and Weaknesses -- 6.3.4 Example of a Cluster-Level Cancer Screening RCT -- 6.4 Pragmatic Randomized Controlled Trials of Cancer Screening -- 6.4.1 Examples of Pragmatic Cancer Screening RCTs -- References -- 7: Observational Research Designs -- 7.1 An Overview of Observational Study Designs -- 7.2 Cohort Studies -- 7.2.1 Design Features -- 7.2.2 Analysis Features -- 7.2.3 Strengths and Weaknesses -- 7.2.4 Variations -- 7.2.5 Examples of Cancer Screening Cohort Studies -- 7.3 Case-Control Studies -- 7.3.1 Design Features -- 7.3.2 Analysis Features -- 7.3.3 Strengths and Weaknesses -- 7.3.4 Example of Case-Control Studies of Cancer Screening -- 7.4 Ecologic Studies -- 7.4.1 Design Features -- 7.4.2 Analysis Features -- 7.4.3 Strengths and Weaknesses -- 7.4.4 Variations -- 7.4.5 Examples of Ecologic Studies of Cancer Screening -- 7.5 Single-Arm Studies -- 7.5.1 Design Features. | |
505 | 8 | |a 7.5.2 Analysis Features -- 7.5.3 Strengths and Weaknesses -- 7.5.4 Variations -- 7.5.5 Examples of Cancer Screening Single-Arm Studies -- 7.6 Two-in-One Single-Arm Studies -- 7.6.1 Design Features -- 7.6.2 Analysis Features -- 7.6.3 Strengths and Weaknesses -- 7.6.4 Examples of Two-in-One Single-Arm Studies -- 7.7 All Study Designs: Critical Data Elements -- References -- 8: Cancer Prevention Screening -- 8.1 Chapter 1: Foundations -- 8.2 Chapter 2: Behind the Scenes -- 8.3 Chapter 3: Performance Measures -- 8.4 Chapter 4: Population Measures: Definitions -- 8.5 Chapter 5: Population Measures: Cancer Screening's Impact -- 8.6 Chapter 6: Experimental Research Designs -- 8.7 Chapter 7: Observational Research Designs -- 8.7.1 Example of a Case-Control Study of Cancer Screening with an Outcome of Invasive Disease -- References -- 9: Additional Considerations -- 9.1 Topics Regarding Data Interpretation -- 9.1.1 Number Needed to Screen -- 9.1.2 Generalizability of Results -- 9.1.3 Concurrent Changes in Treatment -- 9.2 Topics Regarding Methodology -- 9.2.1 Microsimulation Modeling -- 9.2.2 Magnitude of Overdiagnosis -- 9.2.3 Incidence and Prevalence Screens -- 9.2.4 Interval Cancers -- 9.3 Topics Regarding Policy -- 9.3.1 Selecting a Cancer Screening Interval -- 9.3.2 De-implementation -- 9.3.3 Reduction in Advanced-Stage Cancer -- 9.3.4 Benefit in the Absence of a Mortality Reduction -- References -- 10: Closing Thoughts -- References. | |
588 | |a Description based on publisher supplied metadata and other sources. | ||
590 | |a Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. | ||
655 | 4 | |a Electronic books. | |
776 | 0 | 8 | |i Print version: |a Marcus, Pamela M. |t Assessment of Cancer Screening |d Cham : Springer International Publishing AG,c2022 |z 9783030945763 |
797 | 2 | |a ProQuest (Firm) | |
856 | 4 | 0 | |u https://ebookcentral.proquest.com/lib/oeawat/detail.action?docID=6947060 |z Click to View |